Skip to main content
Top

Integrative Analysis of 18F-FDG PET Radiomics and mRNA Expression in Recurrent/Metastatic Oral Squamous Cell Carcinoma: A Cross-Sectional Study

  • Open Access
  • 14-05-2025
  • Research Article
Published in:

Abstract

Background

This study explored the relationship between mRNA expression profiles obtained through next-generation sequencing (NGS) and 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) texture analysis in patients with treatment-resistant oral squamous cell carcinoma (OSCC) who were treated with molecular-targeted drugs. We analyzed the correlation between 18F-FDG PET texture features and NGS data in a small cohort of five patients with recurrent or metastatic OSCC who received molecular-targeted drugs after surgery. Patients were categorized into two groups based on treatment response: responders (n = 3) and non-responders (n = 2). To validate our findings, we examined transcriptomic data from 292 OSCC patients in The Cancer Genome Atlas (TCGA) database.

Results

The gene ankyrin repeat and SOCS box containing two (ASB2) was significantly overexpressed in non-responders and strongly correlated with specific PET radiomic features, including GLRLM_GLNU, GLRLM_RLNU, and GLZLM_GLNU (p < 0.05). High ASB2 expression was also associated with poor prognosis in OSCC patients (p < 0.05) and decreased overall survival, as shown by Kaplan–Meier analysis of the TCGA database (p = 0.017).

Conclusions

Integrating ASB2 expression data with 18F-FDG PET texture features could potentially improve the prediction of treatment outcomes in treatment-resistant OSCC patients undergoing molecular-targeted therapy.
Title
Integrative Analysis of 18F-FDG PET Radiomics and mRNA Expression in Recurrent/Metastatic Oral Squamous Cell Carcinoma: A Cross-Sectional Study
Authors
Mai Kim
Wenchao Gu
Reika Kawabata- Iwakawa
Shinichiro Kina
Takahito Nakajima
Tetsuya Higuchi
Masaru Ogawa
Keisuke Suzuki
Yoshito Tsushima
Satoshi Yokoo
Publication date
14-05-2025
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 3/2025
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-025-02012-5
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

1.75 AMA PRA Category 1 Credits

Explore using biomarker testing to interpret results and guide treatment strategies through an interactive patient simulation and unique educational escape rooms.

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Lilly
Learn more TODO (Link opens in a new window)

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Lilly
Learn more TODO (Link opens in a new window)
Image Credits
Alzheimer’s disease in the biomarker era: preparing the multidisciplinary care team/© Springer Healthcare IME, Navigating neuroimaging in Alzheimer’s care: Practical applications and strategies for integration/© Springer Health+ IME